John Steren Epstein Becker Law Firm Health Care Litigation

E. John Steren

Member

Epstein Becker & Green, P.C.

Website

www.ebglaw.com

Organization Profile

Full Profile

Connect

Email

202-861-1825

Professional Biography

E. John Steren is a Member of the Firm in the Health Care & Life Sciences and Litigation & Business Disputes practices, in the Washington, DC, office of Epstein Becker Green. Mr. Steren devotes a significant portion of his practice to helping health care organizations manage the antitrust risks of joint ventures and other business arrangements. He also focuses his practice on other complex commercial and civil litigation matters.

More Legal and Business Bylines From E. John Steren

FTC Challenges Merger Based on Potential Coordinated Effects Theory, Accepts Conduct Remedy - (Posted On Thursday, July 10, 2025)
Agencies’ Listening Sessions to Focus on Lowering Drug Prices Through Competition - (Posted On Monday, June 23, 2025)
Commissioner Meador Dispels Myths About Antitrust Enforcement - (Posted On Thursday, June 05, 2025)
FTC and DOJ Direct Agency Heads to Identify Anticompetitive Regulations for Elimination—Including in Health Care - (Posted On Thursday, May 15, 2025)
Mark Meador Confirmed as FTC Commissioner - (Posted On Thursday, May 01, 2025)
FTC Issues RFI on Anti-Competitive Regulations - (Posted On Thursday, April 17, 2025)
President Trump Fires Two Commissioners and Solidifies Control Over FTC - (Posted On Friday, April 04, 2025)
Opposition to Renewed COPA Application in Indiana Reveals FTC Leadership’s Views on Hospital Merger Enforcement - (Posted On Thursday, April 03, 2025)
Trump Fires Two Commissioners and Solidifies Control Over FTC - (Posted On Thursday, March 20, 2025)
Revised HSR Thresholds Now in Effect - (Posted On Thursday, March 06, 2025)

FTC Regulation

FTC Coverage and Updates

The National Law Review awards Epstein Becker & Green attorneys E. John Steren and Patricia M. Wagner with a Go-To Thought Leadership award for their coverage of a range of competition law topics including personnel changes at the FTC and the large uptick in Hart-Scott-Rodino (“HSR”) filings the FTC received in 2021. Exceptionally helpful to the NLR's readers in 2021 were Mr. Steren's & Ms. Wagner's actionable insights on how the new direction at the FTC impacts the pharmaceutical and healthcare industries.